Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment

• Published in: BMC cancer Vol. 22; no. 1; pp. 1220 - 9
• Main Authors: Bahmanyar, Maryam, Vakil, Mohammad Kazem, Al-Awsi, Ghaidaa Raheem Lateef, Kouhpayeh, Seyed Amin, Mansoori, Yaser, Mansoori, Behnam, Moravej, Ali, Mazarzaei, Abdulbaset, Ghasemian, Abdolmajid
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25-11-2022; BioMed Central; BMC
• Subjects: Antigens; Cancer; CAR NK cells; Care and treatment; Chemotherapy; Chimeric antigen receptors; Clinical trials; Combination therapies; Cytokines; Cytotoxicity; Genotypes; Graft-versus-host reaction; Growth factors; Health aspects; Histocompatibility antigen HLA; Humans; Hypoxia; Immunotherapy; Immunotherapy, Adoptive - adverse effects; Innate immunity; Killer cells; Killer Cells, Natural; Leukemia; Ligands; Lymphocytes; Lymphocytes T; Lymphopenia; Malignancy; Melanoma; Melanoma - etiology; Melanoma - therapy; Metastasis; Natural killer cells; Neurotoxicity; Patients; Proteins; Radiation; Receptors, Chimeric Antigen - genetics; Tumor Microenvironment; Tumors; Iran; Chimeric antigen receptors; CAR NK cells; Natural killer cells; Combination therapies; Melanoma
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-022-10320-0

Owing to non-responsiveness of a high number of patients to the common melanoma therapies, seeking novel approaches seem as an unmet requirement. Chimeric antigen receptor (CAR) T cells were initially employed against recurrent or refractory B cell malignancies. However, advanced stages or pretreated patients have insufficient T cells (lymphopenia) amount for collection and clinical application. Additionally, this process is time-consuming and logistically cumbersome. Another limitation of this approach is toxicity and cytokine release syndrome (CRS) progress and neurotoxicity syndrome (NS). Natural killer (NK) cells are a versatile component of the innate immunity and have several advantages over T cells in the application for therapies such as availability, unique biological features, safety profile, cost effectiveness and higher tissue residence. Additionally, CAR NK cells do not develop Graft-versus-host disease (GvHD) and are independent of host HLA genotype. Notably, the NK cells number and activity is affected in the tumor microenvironment (TME), paving the way for developing novel approaches by enhancing their maturation and functionality. The CAR NK cells short lifespan is a double edge sword declining toxicity and reducing their persistence. Bispecific and Trispecific Killer Cell Engagers (BiKE and Trike, respectively) are emerging and promising immunotherapies for efficient antibody dependent cell cytotoxicity (ADCC). CAR NK cells have some limitations in terms of expanding and transducing NK cells from donors to achieve clinical response. Clinical trials are in scarcity regarding the CAR NK cell-based cancer therapies. The CAR NK cells short life span following irradiation before infusion limits their efficiency inhibiting their in vivo expansion. The CAR NK cells efficacy enhancement in terms of lifespan TME preparation and stability is a goal for melanoma treatment. Combination therapies using CAR NK cells and chemotherapy can also overcome therapy limitations.